Rationale for development of a synthetic vaccine against plasmodium falciparum malaria

dc.contributor.authorZavala, F.
dc.contributor.authorTam, J.P.
dc.contributor.authorHollingdale, M.R.
dc.contributor.authorCochrane, A.H.
dc.contributor.authorQuakyi, I.A.
dc.contributor.authorNussenzweig, R.S.
dc.contributor.authorNussenzweig, V.
dc.date.accessioned2013-06-21T18:13:57Z
dc.date.accessioned2017-10-16T12:26:52Z
dc.date.available2013-06-21T18:13:57Z
dc.date.available2017-10-16T12:26:52Z
dc.date.issued1985
dc.description.abstractProtective immunity against malaria can be obtained by vaccination with irradiated spoorozoites. The protective antigens known as circumsprozoite (CS) proteins, are polypeptides that cover the surface membrane of the parasite. The CS proteins contain species-specific immunodominant epitopes formed by tandem repeated sequences of amino acids. Here it is shown that the dominant epitope of Plasmodium falciparum is contained in the synthetic dodecapeptide Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro-Asn-Ala-Asn-Pro or (NANP)3. Monoclonal antibodies and most or all polyclonal human antobodies to the sporozoites react with (NANP)3, and polyclonal antibodies raised against the synthetic peptide (NANP)3 react with the surface of the parasite and neutralize its infectivity. Since (NANP)3 repeats are present in CS proteins of P. falciparum from many parts of the world, this epitope is a logical target for vaccine development.en_US
dc.identifier.citationZavala, F., Tam, J. P., Hollingdale, M. R., Cochrane, A. H., Quakyi, I.,Nussenzweig, R. S., &Nussenzweig, V. (1985). Rationale for development of a synthetic vaccine aggainst plasmodium falciparum malaria. Science, 228(4706), 1436-1440en_US
dc.identifier.urihttp://197.255.68.203/handle/123456789/3924
dc.language.isoenen_US
dc.publisherScienceen_US
dc.subjectEMTREE drug terms: immunoglobulin g i 125; malaria vaccine; monoclonal antibody; parasite antigen; peptide; radioisotope; unclassified drugen_US
dc.subjectEMTREE medical terms: animal cell; article; drug efficacy; drug resistance; drug therapy; immunity; nonhuman; Plasmodium falciparum; priority journal; protozoon; sporozoite; therapy; vaccine productionen_US
dc.subjectMeSH: Adult; Antibodies, Monoclonal; Child; Epitopes; Humans; Malaria; Peptides; Plasmodium falciparum; Vaccinesen_US
dc.titleRationale for development of a synthetic vaccine against plasmodium falciparum malariaen_US
dc.typeArticleen_US

Files

License bundle
Now showing 1 - 2 of 2
No Thumbnail Available
Name:
license.txt
Size:
1.82 KB
Format:
Item-specific license agreed upon to submission
Description:
No Thumbnail Available
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description: